ArticleDrug delivery and translational research2026
Bisphosphonates loaded nanoparticles in microparticles: a potential macrophage targeting and repolarizing drug delivery system.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bisphosphonates (BPs) are widely used in treating bone-related conditions, with emerging evidence supporting their potential in treating both skeletal and extra-skeletal diseases. However, their clinical utility is limited by high cytotoxicity, particularly toward macrophages, leading to immune system disruption upon frequent use. This limitation highlights the need for an effective drug delivery system. While nanoparticle formulations improve pharmacokinetics and biodistribution, they often suffer from limited drug loading capacity, poor sustained-release ability, and increased cytotoxicity due to their rapid and excessive intracellular uptake.Here, we present a multifunctional formulation, composed of calcium-zoledronic acid nanoparticles (CaZol NP) encapsulated within polymeric microparticles (CaZol NiM), designed to address many challenges associated with therapeutic use of zoledronic acid (Zol). CaZol NiM improves cellular uptake of Zol, facilitates pH sensitive sustained release of Zol and allows ligand mediated uptake by macrophages. The controlled release of Zol from CaZol NiM effectively reduces Zol's cytotoxic effects on macrophages, enabling their immune modulation by suppressing NF-κB and reactive oxygen species (ROS) activity, while promoting macrophage repolarization from their pro-inflammatory M1 state.Altogether, these findings highlight the potential of CaZol NiM in minimizing off-target effect and expand the clinical applications of Zol in managing both skeletal and extra-skeletal inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.